Marc-Oliver Grimm, Gunhild von Amsberg, Hendrik Heers, Stephan Degener, Florian Roghmann, Jozefina Casuscelli, Steffen Rausch, Marinela Augustin, Lothar Haeberle, Katharina Leucht, Andrea Roessler, Friedemann Zengerling. "3-weekly docetaxel 75 mg/m
                    <sup>2</sup>
                    vs 2-weekly docetaxel 50 mg/m
                    <sup>2</sup>
                    in combination with darolutamide + ADT in patients with mHSPC: Subgroup analyses from the randomised phase 3 ARASAFE trial.." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.7_suppl.153